CELG News and Press, Celgene Corporation From 06/04/19

We’re enjoying our research on BioSig ( BSGM ) and its electrophysiology device, the PURE EP, which we believe has little to no usefulness. The information that we keep coming across continues to be juicy and new developments are occurring. If you missed our previous BioSig report pu...

The FDA accepts for review Celgene's (NASDAQ: CELG ) marketing application seeking approval for luspatercept for beta-thalassemia and myelodysplastic syndromes. More news on: Celgene Corporation, Acceleron Pharma Inc., Healthcare stocks news, Read more ...

U.S. Food and Drug Administration grants priority review for beta-thalassemia indication and sets target action date of December 4, 2019 U.S. Food and Drug Administration sets target action date of April 4, 2020 for myelodysplastic syndromes indication Luspatercept EU Marketing Au...

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...

Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib. This updated analysis of fe...

Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including immunomodulatory agents, proteasome inhibitors and anti-CD38 agents Celgene Corporation (NASDAQ: CELG) today announced the first clinic...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol...

The FDA approves Celgene's ( CELG -0.2% ) REVLIMID (lenalidomide), combined with a rituximab product (a therapy called R 2 ), for previously treated adult patients with follicular lymphoma or marginal zone lymphoma. More news on: Celgene Corporation, Bristol-Myers Squibb Company, ...

Approval marks the first chemotherapy-free combination regimen for patients who have relapsed or did not respond to previous treatment Approval based on Phase 3 AUGMENT study, which showed the combination significantly improved median progression-free survival versus rituximab monother...